Literature DB >> 21762361

Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database.

Emmeline A Garcia1, Julio R Lopez, Joy L Meier, Arthur L M Swislocki, David Siegel.   

Abstract

A pharmacy database was used to identify patients with resistant hypertension who could then be tested for the presence of primary hyperaldosteronism. Inclusion criteria were: (1) resistant hypertension defined as uncontrolled hypertension and use of 3 antihypertensive medication classes or ≥ 4 antihypertensive classes regardless of blood pressure; (2) low or normal potassium levels (≤ 4.9 mEq/L); and (3) continuous health care from October 1, 2008, to February 28, 2009. Exclusion criteria were: (1) past or current use of an aldosterone antagonist, or (2) a medication possession ratio (adherence) <80% for any antihypertensive drug. Hyperaldosteronism was classified as an aldosterone/renin ratio (ARR) ≥ 30. Using the computer, 746 patients were identified who met criteria. After manual chart review to verify inclusion and exclusion criteria, 333 patients remained. Of 184 individuals in whom an ARR was obtained, 39 (21.2%) had a ratio of ≥ 30. A computer database is useful to identify patients with resistant hypertension and those who may have primary aldosteronism.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762361      PMCID: PMC8108800          DOI: 10.1111/j.1751-7176.2011.00443.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  20 in total

1.  Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.

Authors:  Paolo Mulatero; Franco Rabbia; Alberto Milan; Cristina Paglieri; Fulvio Morello; Livio Chiandussi; Franco Veglio
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

Review 2.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

3.  Role for adrenal venous sampling in primary aldosteronism.

Authors:  William F Young; Anthony W Stanson; Geoffrey B Thompson; Clive S Grant; David R Farley; Jon A van Heerden
Journal:  Surgery       Date:  2004-12       Impact factor: 3.982

4.  Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome).

Authors:  R K Lingam; S A Sohaib; A G Rockall; A M Isidori; S Chew; J P Monson; A Grossman; G M Besser; R H Reznek
Journal:  Eur Radiol       Date:  2004-07-06       Impact factor: 5.315

Review 5.  Glucocorticoid-remediable aldosteronism.

Authors:  Graham T McMahon; Robert G Dluhy
Journal:  Cardiol Rev       Date:  2004 Jan-Feb       Impact factor: 2.644

Review 6.  Clinical manifestation of aldosteronoma.

Authors:  Maha Al Fehaily; Quan-Yang Duh
Journal:  Surg Clin North Am       Date:  2004-06       Impact factor: 2.741

7.  Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.

Authors:  Lysann Seiler; Lars C Rump; Jürgen Schulte-Mönting; Marc Slawik; Katrin Borm; Hermann Pavenstädt; Felix Beuschlein; Martin Reincke
Journal:  Eur J Endocrinol       Date:  2004-03       Impact factor: 6.664

8.  Outpatient screening tests for primary aldosteronism.

Authors:  P J Dunn; E A Espiner
Journal:  Aust N Z J Med       Date:  1976-04

9.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.

Authors:  John W Funder; Robert M Carey; Carlos Fardella; Celso E Gomez-Sanchez; Franco Mantero; Michael Stowasser; William F Young; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-06-13       Impact factor: 5.958

10.  Primary aldosteronism and hypertensive disease.

Authors:  Lorena Mosso; Cristian Carvajal; Alexis González; Adolfo Barraza; Fernando Avila; Joaquín Montero; Alvaro Huete; Alessandra Gederlini; Carlos E Fardella
Journal:  Hypertension       Date:  2003-06-09       Impact factor: 10.190

View more
  1 in total

Review 1.  Exploring issues in difficult-to-treat hypertension.

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-30       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.